Literature DB >> 20824412

[Systemic mastocytosis--definition of an internal disease].

Jürgen Homann1, Ulrich W Kolck, Andreas Ehnes, Thomas Frieling, Martin Raithel, Gerhard J Molderings.   

Abstract

Systemic mastocytosis comprises disorders characterized by an accumulation of genetically altered mast cells in all organs and tissues due to an increased proliferation rate and reduced apoptosis of those pathologic mast cells. Release of their mediators can effectively influence organ function and can lead to systemic effects without inducing traces in routinely used laboratory parameters or imaging methods. In most cases, little invasive investigations allow diagnosing the disease and, hence, an appropriate therapy consisting of a basic medication with antihistamine and mast cell membrane-stabilizing compounds that should be supplemented, if required, by a medication adapted to individual symptoms, can be initiated. Because of the probably high prevalence of the disorder, systemic mastocytosis should be considered as a differential diagnosis in particular in the case of chronic gastrointestinal complaints such as abdominal pain/discomfort possibly associated with diarrhea, at an early stage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20824412     DOI: 10.1007/s00063-010-1093-8

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  29 in total

Review 1.  Pathogenesis of irritable bowel syndrome: the mast cell connection.

Authors:  Javier Santos; Mar Guilarte; Carmen Alonso; J R Malagelada
Journal:  Scand J Gastroenterol       Date:  2005-02       Impact factor: 2.423

Review 2.  Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.

Authors:  Jason Gotlib; N C P Cross; D Gary Gilliland
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

3.  [Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases].

Authors:  G Delling; H Ritzel; M Werner
Journal:  Pathologe       Date:  2001-03       Impact factor: 1.011

Review 4.  Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network.

Authors:  Hugh Rosen; Edward J Goetzl
Journal:  Nat Rev Immunol       Date:  2005-07       Impact factor: 53.106

Review 5.  Current options in the treatment of mast cell mediator-related symptoms in mastocytosis.

Authors:  Luis Escribano; Cem Akin; Mariana Castells; Lawrence B Schwartz
Journal:  Inflamm Allergy Drug Targets       Date:  2006-01

6.  New aspects of liver abnormalities as part of the systemic mast cell activation syndrome.

Authors:  Kirsten Alfter; Ivar von Kügelgen; Britta Haenisch; Thomas Frieling; Alexandra Hülsdonk; Ulrike Haars; Arndt Rolfs; Gerhard Noe; Ulrich W Kolck; Jürgen Homann; Gerhard J Molderings
Journal:  Liver Int       Date:  2008-07-23       Impact factor: 5.828

7.  Cysteinyl leukotrienes enhance the degranulation of bone marrow-derived mast cells through the autocrine mechanism.

Authors:  Izumi Kaneko; Kaori Suzuki; Kaori Matsuo; Hiroyuki Kumagai; Yuji Owada; Naoya Noguchi; Takanori Hishinuma; Masao Ono
Journal:  Tohoku J Exp Med       Date:  2009-03       Impact factor: 1.848

8.  Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow.

Authors:  Malisha R Johnson; Srdan Verstovsek; Jeffrey L Jorgensen; T Manshouri; Raja Luthra; Dan M Jones; Carlos E Bueso-Ramos; L Jeffrey Medeiros; Yang O Huh
Journal:  Mod Pathol       Date:  2008-09-19       Impact factor: 7.842

9.  Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.

Authors:  Luis Escribano; Iván Alvarez-Twose; Laura Sánchez-Muñoz; Andres Garcia-Montero; Rosa Núñez; Julia Almeida; Maria Jara-Acevedo; Cristina Teodósio; Mónica García-Cosío; Carmen Bellas; Alberto Orfao
Journal:  J Allergy Clin Immunol       Date:  2009-07-09       Impact factor: 10.793

10.  Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient?

Authors:  Joseph H Butterfield; Chin-Yang Li
Journal:  Am J Clin Pathol       Date:  2004-02       Impact factor: 2.493

View more
  4 in total

Review 1.  [Surgical interventions in patients with mast cell activation disease. Aspects relevant for surgery using the example of a cholecystectomy].

Authors:  B Sido; F L Dumoulin; J Homann; H-J Hertfelder; M Bollmann; G J Molderings
Journal:  Chirurg       Date:  2014-04       Impact factor: 0.955

2.  Intravenous infusion of ascorbic acid decreases serum histamine concentrations in patients with allergic and non-allergic diseases.

Authors:  Alexander F Hagel; Christian M Layritz; Wolfgang H Hagel; Hans-Jürgen Hagel; Edith Hagel; Wolfgang Dauth; Jürgen Kressel; Tanja Regnet; Andreas Rosenberg; Markus F Neurath; Gerhard J Molderings; Martin Raithel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05-11       Impact factor: 3.000

Review 3.  Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.

Authors:  Gerhard J Molderings; Stefan Brettner; Jürgen Homann; Lawrence B Afrin
Journal:  J Hematol Oncol       Date:  2011-03-22       Impact factor: 17.388

4.  Health-related quality of life and health literacy in patients with systemic mastocytosis and mast cell activation syndrome.

Authors:  Rupert Conrad; Martin Mücke; Tobias Jürgen Schmidt; Julia Sellin; Gerhard J Molderings
Journal:  Orphanet J Rare Dis       Date:  2022-07-29       Impact factor: 4.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.